1-45333452-C-T
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_001128425.2(MUTYH):c.309G>A(p.Trp103*) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000279 in 1,614,102 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001128425.2 stop_gained
Scores
Clinical Significance
Conservation
Publications
- familial adenomatous polyposis 2Inheritance: AD, AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen, G2P
- colorectal cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
- familial ovarian cancerInheritance: AD, AR Classification: NO_KNOWN Submitted by: ClinGen
- hereditary breast carcinomaInheritance: AD, AR Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_001128425.2. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MUTYH | NM_001128425.2 | MANE Plus Clinical | c.309G>A | p.Trp103* | stop_gained | Exon 3 of 16 | NP_001121897.1 | ||
| MUTYH | NM_001048174.2 | MANE Select | c.225G>A | p.Trp75* | stop_gained | Exon 3 of 16 | NP_001041639.1 | ||
| MUTYH | NM_012222.3 | c.300G>A | p.Trp100* | stop_gained | Exon 3 of 16 | NP_036354.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MUTYH | ENST00000710952.2 | MANE Plus Clinical | c.309G>A | p.Trp103* | stop_gained | Exon 3 of 16 | ENSP00000518552.2 | ||
| MUTYH | ENST00000456914.7 | TSL:1 MANE Select | c.225G>A | p.Trp75* | stop_gained | Exon 3 of 16 | ENSP00000407590.2 | ||
| MUTYH | ENST00000372098.7 | TSL:1 | c.300G>A | p.Trp100* | stop_gained | Exon 3 of 16 | ENSP00000361170.3 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152212Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251488 AF XY: 0.00000736 show subpopulations
GnomAD4 exome AF: 0.0000301 AC: 44AN: 1461890Hom.: 0 Cov.: 35 AF XY: 0.0000358 AC XY: 26AN XY: 727246 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152212Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74350 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Familial adenomatous polyposis 2 Pathogenic:8
This sequence change creates a premature translational stop signal (p.Trp103*) in the MUTYH gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MUTYH are known to be pathogenic (PMID: 18534194, 20663686). This variant is present in population databases (rs748170941, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with adenomatous polyposis (PMID: 15761860). This variant is also known as G267A (W89X). ClinVar contains an entry for this variant (Variation ID: 184976). For these reasons, this variant has been classified as Pathogenic.
This variant changes 1 nucleotide in exon 3 of the MUTYH gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, this variant has been reported in individuals affected with colorectal polyposis (PMID: 15761860). This variant has been identified in 1/251488 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MUTYH function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
The p.Trp103X variant in MUTYH has been reported in the compound heterozygous state in 1 individual with MUTYH-associated polyposis (Aretz 2006, Vogt 2009, Sutcliffe 2019). It has been identified in 0.001% (1/113764) of chromosomes in Europeans by gnomAD (http://gnomad.broadinstitute.org).This variant has also been reported in ClinVar (Variation ID 184976). This nonsense variant leads to a premature termination codon at position 103, which is predicted to lead to a truncated or absent protein. Loss of function of the MUTYH gene is an established disease mechanism in autosomal recessive MUTYH-associated polyposis. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive MUTYH-associated polyposis. ACMG/AMP criteria applied: PVS1, PM2, PM3.
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.
Variant summary: MUTYH c.309G>A (p.Trp103X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 4e-06 in 251488 control chromosomes. c.309G>A has been reported in the literature in at least one individual affected with MUTYH-Associated Polyposis (Kairupan_2005). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 15761860). Nine clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified as Pathogenic (n=6), Likely Pathogenic (n=2) and VUS (n=1. Based on the evidence outlined above, the variant was classified as pathogenic.
not provided Pathogenic:3
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 28152038, 34761457, 32885271, 15761860)
The MUTYH p.Trp103* variant was identified in 1 of 364 proband chromosomes (frequency: 0.003) from individuals or families with adenomatous polyposis (Kairupan 2005). The individual identified in this study was a compound heterozygote with a second pathogenic MUTYH mutation, p.Gly382Asp.The variant was also identified in dbSNP (ID: rs748170941) as "With Pathogenic allele ", ClinVar (classified as pathogenic by Invitae, Ambry Genetics and three other submitters; as likely pathogenic by Counsyl), and in the COGR database. The variant was not identified in Cosmic, or UMD-LSDB. The variant was identified in control databases in 1 of 246268 chromosomes at a frequency of 0.000004 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the European in 1 of 111716 chromosomes (freq: 0.000009), but not in other populations. The p.Trp103* variant leads to a premature stop codon at position 103, which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants in the MUTYH gene are an established mechanism of disease in MUTYH-associated polyposis. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.
Hereditary cancer-predisposing syndrome Pathogenic:2
The p.W103* pathogenic mutation (also known as c.309G>A), located in coding exon 3 of the MUTYH gene, results from a G to A substitution at nucleotide position 309. This changes the amino acid from a tryptophan to a stop codon within coding exon 3. This alteration was reported in conjunction with an MUTYH founder mutation in an Australian woman with early-onset adenomatous polyposis (Kairupan CF et al. Int. J. Cancer, 2005 Aug;116:73-7). This alteration was also identified in an individual diagnosed with pancreatic cancer (Lerner-Ellis J et al. J Cancer Res Clin Oncol, 2021 Mar;147:871-879). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
This variant changes 1 nucleotide in exon 3 of the MUTYH gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in an individual affected with colorectal polyposis in compound heterozygous state with a known pathogenic variant p.Gly382Asp (PMID: 15761860). This variant has been identified in 1/251488 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MUTYH function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Gastric cancer;C3272841:Familial adenomatous polyposis 2 Pathogenic:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at